Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2115 of 8930 results

  1. Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

    Awaiting development Reference number: GID-TA10916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development Reference number: GID-TA10966 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development Reference number: GID-TA10998 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development Reference number: GID-TA11160 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development Reference number: GID-TA11216 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development Reference number: GID-TA11218 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development Reference number: GID-TA11219 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development Reference number: GID-TA11300 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development